Home » Newsletters » BioWorld Science

BioWorld Science

May 2, 2022

View Archived Issues

BBT-207, a fourth-generation EGFR TKI with activity against most common mutants

Bristol Myers Squibb describes new FPR1/2 agonists

New KCNA3 channel blockers identified at DE Shaw Research

Vertex Pharmaceuticals discovers CFTR modulators

Curome Biosciences presents new quinone derivatives

New mucolipin-1 activators identified at Lysoway Therapeutics

Innate immune memory underlies inflammatory comorbidities: study

CF-370 shows synergy with amikacin in drug-resistant P. aeruginosa acute pneumonia model

BioNova Pharmaceuticals menin inhibitor BNM-1192 shows promise for MLL rearranged leukemias

Bridge Biotherapeutics and Cyrus Therapeutics generate next-generation EGFR degraders

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...